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ABSTRACT
Thymic stromal lymphopoietin (TSLP) has emerged as an important, but 
contradictory, player conditioning tumor growth. In certain contexts, by driving T 
helper (h) 2 responses via tumor-associated OX40 Ligand (OX40L)+ dendritic cells 
(DCs), TSLP may play a pro-tumorigenic role. The study elucidates the importance 
of TSPL in pancreatic ductal adenocarcinoma (PDAC), by analyzing: i) TSLP levels 
in PDAC cell-line supernatants and plasma from patients with locally-advanced/
metastatic PDAC, pre- and post-treatment with different chemotherapeutic protocols, 
in comparison with healthy donors; ii) TSLP and OX40L expression in PDAC and 
normal pancreatic tissues, by immunohistochemistry; iii) OX40L expression on ex 
vivo-generated normal DCs in the presence of tumor-derived TSLP, by flow cytometry; 
iv) clinical relevance in terms of diagnostic and prognostic value and influence on 
treatment modality and response.
Some PDAC cell lines, such as BxPC-3, expressed both TSLP mRNA and protein. 
Normal DCs, generated ex vivo in the presence of TSLP-rich-cell supernatants, displayed 
increased expression of OX40L, reduced by the addition of a neutralizing anti-TSLP 
polyclonal antibody. OX40L+ cells were detected in pancreatic tumor inflammatory 
infiltrates. Abnormally elevated TSLP levels were detected in situ in tumor cells and, 
systemically, in locally-advanced/metastatic PDAC patients. Of the chemotherapeutic 
protocols applied, gemcitabine plus oxaliplatin (GEMOX) significantly increased 
circulating TSLP levels. Elevated plasma TSLP concentration was associated with 
shorter overall survival and increased risk of poor outcome. Plasma TSLP measurement 
successfully discriminated PDAC patients from healthy controls.
These data show that TSLP secreted by pancreatic cancer cells may directly 
impact PDAC biology and patient outcome. 
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INTRODUCTION
Tumor-related inflammation frequently exhibits 
profiles that promote tumor growth and protect malignant 
cells from the immune system [1]. Cancer cells can create a 
favorable microenvironment by co-opting cells of the innate 
immune system, such as myeloid-derived suppressor cells, 
to become components of the pro-tumorigenic stroma [2]. 
They can also avoid the host’s tumor-specific T-cells by 
skewing the acquired immune response from cytotoxic T 
helper (h) 1 toward the permissive Th2 phenotype, and/or 
by inducing immunosuppressive regulatory T cells (Treg) [3].
Pancreatic adenocarcinoma (PDAC) is one of the 
deadliest epithelial cancers, because of the advanced 
stage at diagnosis, early systemic dissemination, and 
poor response to chemo/radio therapy. Clinical and 
experimental evidence support the occurrence of profound 
local and systemic immune-response alterations in PDAC 
patients [4–7].
Thymic stromal lymphopoietin (TSLP) was 
originally identified as a murine thymic stroma-secreted 
cytokine having regulatory functions on the growth and 
differentiation of B cells and the proliferation of T cells 
[8]. More recently, it was found to be highly expressed 
also outside the thymus, namely by epithelial cells of 
the lung, intestine and skin, and by fibroblasts, mast 
cells, and smooth muscle cells [9]. It is recognized as 
a critical mediator involved in the maintenance of Th2-
type homeostasis at barrier surfaces [10]. In humans, 
TSLP contributes to the onset of allergic inflammatory 
diseases, by activating CD4+ T cells and inducing their 
Th2 differentiation [11]. This can occur either directly 
[12], or indirectly via the education of immature myeloid-
derived DCs, the major TSLP-responsive cellular subset 
[13]. It is known that DCs play a critical role in polarizing 
Th effector cells, depending on their specific profile of 
cytokines and co-stimulatory molecules, and on the 
influence of the individual tissue milieu from which they 
originate. DCs treated in vitro with TSLP fail to produce 
the Th1-polarizing cytokine Interleukin (IL)-12, and 
up-regulate the expression of OX40 ligand (OX40L). 
This ligand is critical for its ability to polarize naïve T 
cells into inflammatory Th2 cells, producing Th2-type 
cytokines like IL-4, IL-5, IL-13, plus Tumor Necrosis 
Factor (TNF)-α [14]. 
For many types of cancers, including PDAC, a Th2 
response predominates over the cytotoxicity induced by 
CD8+ T cells and the Th1 response. Generally, tumors 
with this phenotype have a worse prognosis than tumors 
in which Th1-type responses predominate [15]. However, 
the mechanism whereby Th2-biased immune responses are 
initiated in tumors remains poorly understood. 
Recent studies in humans show that TSLP, being 
expressed in the tumor microenvironment, plays a role in 
promoting a Th2-like environment in the tumor. A study 
on pancreatic cancer, in which a Th2 (GATA3+) cellular 
infiltrate is predominant, identified a central role for 
cancer-associated fibroblasts (CAFs) in conditioning DCs 
with Th2-polarizing capability, via TSLP secretion [16]. 
In vitro, supernatants from CAF induced myeloid DCs to 
up-regulate the TSLP receptor (TSLPR), to secrete Th2-
attracting chemokines, and to acquire a TSLP-dependent 
Th2-polarizing capability [16]. Importantly, in vivo, 
TSLPR-expressing DCs were found be present in the tumor 
stroma and in tumor-draining lymph nodes, but not in non-
draining lymph nodes [16]. Moreover, this Th2 immune 
deviation plays an active role in tumor progression, and has 
been found to reduce patient survival [16]. However, the 
role of TSLP in cancer appears increasingly controversial, 
even paradoxical, as it exerts either pro- or anti-tumorigenic 
effects, depending on the context [17].
The current study sought to elucidate the importance 
of TSPL in PDAC development and progression, by 
analyzing expression of the cytokine in vitro and in vivo, 
and examining its clinical relevance in terms of diagnostic 
power, prognostic value, and influence on treatment 
modalities. 
RESULTS 
PDAC cell lines express TSLP at mRNA and 
protein levels
TSLP mRNA expression levels were first analyzed 
quantitatively in the established PDAC cell lines BxPC-3, 
PT-45, and Capan-2, using real time RT-PCR. As shown in 
Figure 1A, large amounts of TSLP transcript were found 
in BxPC-3 cells, minimal amounts in PT-45, and almost 
none in Capan-2 cells. To determine whether mRNA 
expression translates into protein production, TSLP levels 
were assessed in the conditioned medium (CM) of the 
three cell lines by specific ELISA. Figure 1B shows that, 
constitutively, BxPC-3 cells released 37.9 ± 6 pg/ml of 
TSLP, PT-45 cells were at the detection limit (8 ± 7 pg/
ml), whereas Capan-2 cells were below the detection limit. 
TSLP release from the non-tumorigenic 
immortalized human pancreatic ductal epithelial cells 
[HPDE6-E6E7 (H6c7)] was also checked; levels in the 
supernatant were undetectable (data not shown). 
 TSLP expression in PDAC tissue samples
In situ TSLP protein expression was then analyzed 
in malignant (n = 38) and normal (n = 8) pancreatic tissue 
specimens. Figure 2A shows representative examples 
of immunohistochemical staining, in PDAC and normal 
pancreas specimens. Seventy three % of PDAC cases 
expressed TSLP on both ductal and stromal cells, 
whereas only 25% of normal pancreas specimens did 
so. The semiquantitative assessment of staining (IRS), 
only evaluated on the ductal normal and malignant cells, 
demonstrated that TSLP levels were significantly higher 
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in PDAC than in normal pancreas [IRS median (range): 
61 (0–261) vs. 0 (0–24), p = 0.005] (Figure 2B). When 
PDAC cases were stratified by disease stage, there was 
no significant difference between groups (Supplementary 
Figure 1, p > 0.05). Conversely, when PDAC were classified 
by degree of tumor differentiation, well-differentiated 
tumors (grade 1) showed greater TSLP expression than 
did poorly-differentiated tumors (grades 2/3 plus 3) [IRS 
median (range): 75 (47–261), vs. 4 (0–150), respectively, p 
< 0.05], while moderately-differentiated tumors (grade 2) 
expressed similar TSLP levels both to well-differentiated 
tumors [IRS median (range) 85 (0–190) vs. 75 (47–261), 
p > 0.05] and poorly-differentiated tumors [IRS median 
(range) 85 (0–190) vs. 4 (0–150), p > 0.05] (Figure 2C).  
OX40L expression in normal DCs in the absence 
or presence of BxPC-3 or Capan-2 cell-CM
Some PDAC cells can release biologically-
significant amounts of TSLP, which can induce expression 
of OX40L in myeloid DCs. In turn, this leads to expansion 
of T cells producing type 2 cytokines, which are not very 
effective at contrasting tumor growth. The effect of CM 
of BxPC-3 and Capan-2 cells (respectively high and low 
TSLP producers) on the ex vivo differentiation of normal 
monocytes into DCs (n = 6) was thus assessed in terms 
of OX40L expression. As Figure 3A shows, only a small 
fraction of DCs generated in the absence of cell line CM 
expressed OX40L (mean % ± SE: 7.0 ± 1.3 HLA-DR+/
OX40L+). Conversely, DCs differentiated in the presence 
of BxPC-3 cell-CM displayed a significant rise in OX40L 
expression vs. untreated DCs (mean % ± SE: 31.0 ± 8.0 
HLA-DR+/OX40L+, p = 0.036). The CM of Capan-2 cell 
line, which produces TSLP in trace amounts, induced a 
slight but not statistically-significant increase in OX40L 
expression in DCs compared to DCs control (mean % ± SE: 
12.2 ± 7.7 HLA-DR+/OX40L+, p = 0.497). The expression 
of OX40L on the surface of DCs generated in the presence 
of BxPC-3 cell-CM was partially, but significantly, reduced 
(34%) by the use of a neutralizing anti-TSLP polyclonal 
antibody with proven blocking efficacy (BxPC-3 cell-CM 
plus anti-TSLP DCs: mean % ± SE 17.8 ± 1.6 vs. BxPC-
Figure 1: Expression of TSLP mRNA and protein in established pancreatic carcinoma cell lines. (A) Cytokine mRNA 
levels in BxPC-3, PT-45 and Capan-2 cells were assessed by real time RT-PCR and normalized to β-actin mRNA levels. Values are means 
(±SD) normalized gene expression. (B) Concentration of TSLP in CM derived from BxPC-3, PT-45, and Capan-2 cells measured by 
ELISA. The mean level (±SD) of cytokine detected in triplicate in CM samples is indicated.
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3 cell-CM DCs: mean % ± SE 26.8 ± 2.8, p = 0.018) 
(Figure 3B and Supplementary Table 1). 
OX40L expression in PDAC tissue samples 
To verify whether TSLP, produced locally by 
malignant pancreatic ductal cells, was also able to induce 
infiltration of OX40L+ cells in vivo, immunohistochemical 
analysis of OX40L was performed on the same tissue 
samples analyzed for TSLP expression. Figure 4A shows 
OX40L immunohistochemical staining of representative 
specimens of malignant and normal pancreas. OX40L 
was mainly expressed in cell cytoplasm and nucleus, as 
has been reported elsewhere [18, 19]. Sixty-one % of 
PDAC cases displayed tumor-associated inflammatory 
cell infiltrate, which was not present in normal pancreatic 
parenchyma. Evaluation of OX40L expression on 
infiltrating inflammatory cells showed positivity in 41% 
of the neoplastic tissues analyzed, with an IRS of 4 (0–60) 
[median (range)]. When the IRS were stratified by 
disease stage, no statistically-significant difference 
was found between groups (Supplementary Figure 2A, 
p > 0.05). When PDAC were classified by degree of tumor 
differentiation (Figure 4B), moderately-differentiated 
tumors showed higher OX40L expression in infiltrating 
inflammatory cells than poorly-differentiated tumors 
[IRS median (range): 9 (0–54) vs. 0 (0–4), p = 0.002]. 
By contrast, no significant difference was found between 
Figure 2: Detection of TSLP in PDAC and normal pancreatic tissues in situ, as determined by IHC. (A) Immunostaining 
of representative samples of PDAC and normal pancreatic tissues (original magnification, ×200). (B) Immunoreactivity scores (IRS) in 
malignant (n = 38) and normal (n = 8) pancreatic tissue samples. P-values obtained by the Mann–Whitney Rank Sum Test. (C) IRS in PDAC 
categorized by tumor differentiation grading. P-values obtained by Kruskal–Wallis One Way Analysis of Variance by Ranks followed by 
Dunn’s Test. Median, 10th, 25th, 75th, and 90th percentiles are presented as vertical boxes with error bars. Dots indicate outliers. 
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well-differentiated and moderately/poorly-differentiated 
tumors [IRS median (range): 4.5 (0–60) vs. 9 (0–54), 
p = 0.317 and vs. 0 (0–4), p = 0.112, respectively].
Interestingly, both normal and malignant ductal 
and acinar cells expressed OX40L (37.5% and 54% of 
cases, respectively), with no significant difference in 
IRS terms (p = 0.430) (Figure 4C). When the IRS of the 
positive tumor cases were stratified by disease stage, 
there was an increasing trend towards the later stages, 
without achieving statistical significance, likely because 
of the high inter-individual expression variations [IRS 
median (range): 0 (0–120), stage I; 9 (0–140), stage II; 75 
(0–104.4), stage III + IV] (Supplementary Figure 2B). 
If the IRS were subdivided by degree of tumor 
differentiation, moderately-differentiated tumors appeared 
to express more OX40L on malignant cells than did well- 
or poorly-differentiated ones [IRS median (range): 0 (0–
140), grade 1; 55 (0–120), grade 2; 0 (0–104.4), grade 2/3 
+ 3, p = 0.041 and p = 0.050, respectively)] (Figure 4D). 
Moreover, a strong positive correlation was found between 
OX40L IRS of inflammatory cell infiltrate and those of 
corresponding tumor cells (Spearman correlation test, 
r = 0.536, p = 0.0006). Unexpectedly, there were no 
statistically-significant correlations between TSLP IRS 
and either inflammatory infiltrate or cancer cell OX40L 
IRS (Spearman correlation test: r = 0.133, p = 0.434; and 
r = –0.150, p = 0.372, respectively).
Elevated plasma TSLP levels in patients with 
locally-advanced or metastatic PDAC
To determine whether the tumor microenvironment 
affects circulating levels of TSLP, basal plasma TSLP 
concentrations were measured in patients with locally-
Figure 3: Effects of BxPC-3 and Capan-2 cell-CM on OX40L expression in ex vivo-generated normal DCs. Incidence 
of OX40L expression on normal HLA-DR+ DCs obtained (A) in the absence (control), and in the presence of 20% BxPC-3 or Capan-2 
cell-CM. Values are means ± SE. P-values obtained by One Way ANOVA followed by Bonferroni t-Test, or (B) in the presence of BxPC-3 
cell-CM, pre-treated with a neutralizing anti-TSLP polyclonal antibody. Values are means ± SE. P-values obtained by the Paired t-Test.
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advanced or metastatic PDAC, and compared with those 
of normal subjects; the former were higher than the 
latter [median (range): 5.74 (0–152.9) pg/ml vs. 4.65 
(0–9.6) pg/ml, p = 0.040] (Figure 5).
Correlation between presence of metastasis and 
plasma TSLP levels
To clarify the clinical significance of these findings 
in locally-advanced or metastatic pancreatic cancer, the 
relationship between presence of metastasis and pre-
chemotherapy (time 0) plasma TSLP levels was evaluated. 
No significant difference and no correlation were detected, 
by the Mann-Whitney test [median (range) non-metastatic 
patients’ TSLP at time 0 vs. metastatic patients’ TSLP at 
time 0: 5.74 (0–38.63) pg/ml vs. 5.74 (0–152.89) pg/ml; 
p = 0.860] and the Spearman correlation test (r = −0.055, 
p = 0.625), respectively. 
Effect of chemotherapy on plasma TSLP
To estimate the possible in vivo modulatory 
influence of chemotherapy on circulating levels 
of TSLP, its plasma concentration was analyzed 
Figure 4: Detection of OX40L in PDAC and normal pancreatic tissues in situ as determined by IHC. (A) Immunostaining 
of representative samples of PDAC and normal pancreatic tissues (original magnification ×200). (B) Immunoreactivity scores (IRS) in 
inflammatory cell infiltrate of PDAC categorized by tumor differentiation grading. (C) IRS in malignant (n = 38) and normal (n = 8) ductal 
cells of pancreatic tissue samples. P-values obtained by the Mann–Whitney Rank Sum Test. (D) IRS in tumor cells of PDAC categorized 
by tumor differentiation grading. P-values obtained by Kruskal–Wallis One Way Analysis of Variance by Ranks followed by Dunn’s Test. 
Median, 10th, 25th, 75th, and 90th percentiles are presented as vertical boxes with error bars. Dots indicate outliers. 
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comparatively pre- (time 0) and post-treatment 
at first restaging (time 1) in 62 patients out of 82 
enrolled. These patients received one of the following 
chemotherapy regimens: GEM (n = 27), GEMOX 
(n = 32), bolus 5-FU + Calcium Levofolinate (n = 2), or 
BEV+CAPE+RT (n = 1). As Table 2 shows, in general 
pre- and post-chemotherapy circulating TSLP levels 
did not differ significantly. When the larger groups, i.e. 
patients treated with GEM or GEMOX were stratified by 
therapeutic protocol, no difference was found between 
plasma levels of TSLP pre- and post-chemotherapy 
in patients treated with GEM alone (p = 0.505). 
Conversely, in the GEMOX group, a statistically-
significant increase in TSLP levels was observed at 
first restaging (p = 0.044) (Table 1). Since this increase 
might be associated to the chemo-resistance that usually 
occurs in patients with advanced disease, the levels 
of TSLP in responsive (n = 11) vs. non-responsive 
(n = 21) PDAC patients under GEMOX treatment were 
compared. A trend towards higher circulating TSLP 
level in non-responsive patients was found, but this 
trend did not reach statistical significance, probably 
because of the small number of cases and the high inter-
individual variation (mean ± SE: 4.96 ± 1.55 vs. 18.82 ± 
8.58, p = 0.257) (Supplementary Figure 3).
Among patients who passed the first restaging after 
GEM or GEMOX treatment (n = 72), 64.7% of those 
treated with GEM went into complete remission (n = 2, 
CR), partial remission (n = 2, PR), or disease stabilization 
(n = 18, SD), with median (range) survival of 329 (117–
1393) days, while 35.3% had disease progression (n = 12, 
DP) with median (range) survival of 160 (43–601) days; 
among patients treated with GEMOX, 34.2% achieved PR 
(n = 2) or SD (n = 11) with median (range) survival of 374 
(169–1175) days, while 65.8% had DP (n = 25), with a 
median (range) survival of 148 (80–514) days.
Objective tumor-response rate and plasma TSLP 
levels
In 72 treated patients (including 2 patients 
treated with BEV+CAPE+RT and 2 with bolus 5-FU + 
Levofolinate calcium) radiologic or clinical response 
was evaluated. Overall, chemotherapy response-rate was 
48.6% (35 responders, comprising 2 CR, 4 PR and 29 SD). 
51.4% of patients (n = 37) were non-responsive with DP. 
No statistically-significant correlation between response 
to chemotherapy and TSLP levels was found (Spearman 
correlation coefficient: r = 0.144, p = 0.228). 
Overall survival and plasma TSLP levels 
Due to the lack of standardized cutoff values 
for TSLP, the 99th percentile from a healthy reference 
population (9.29 pg/ml) was taken arbitrarily in this study 
as cutoff for prognostic assessment. Kaplan-Meier curves 
for overall patient survival, combined with univariate 
analysis, showed that patients with high plasma TSLP 
levels (≥9.29 pg/ml) had significantly shorter overall 
survival (p = 0.024) (Figure 6). Additionally, multivariate 
analysis with Cox regression model, adjusting for 
age, gender, radical surgery, metastasis, stage, and 
Figure 5: Plasma levels of TSLP. Basal circulating TSLP levels in PDAC patients (n = 82) and healthy donors (n = 41) as determined 
by ELISA. P-values obtained by the Mann-Whitney Rank Sum Test. Median, 10th, 25th, 75th, and 90th percentiles are presented as vertical 
boxes with error bars. Dots indicate outliers.
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chemotherapy (any treatment, computed as dichotomous 
variable), showed that TSLP levels were statistically 
independent predictive factors for poorer prognosis for 
PDAC. [Hazard ratio (HR) = 1.986; 95% confidence 
interval (CI) 1.012–4.016; p = 0.036].
Diagnostic value of TSLP as a plasmatic 
biomarker for PDAC
To further evaluate the potential clinical utility of 
TSLP as diagnostic serum marker, ROC curve analysis 
was used to discriminate between PDAC patients and 
healthy volunteers. The cutoff value of 4.76 ng/ml was 
associated with the highest diagnostic accuracy [p = 0.04, 
Area Under Curve (AUC) = 0.6129, sensitivity 61%, 
specificity 60%].
DISCUSSION
This explorative study found that PDAC cells 
themselves, both in vitro and in situ, can elaborate TSLP, 
a cytokine known to promote type 2 activation/maturation 
of resident tumor DCs. This original finding offers a fresh 
interpretation of the aberrant deviation of immunity that, 
in this cancer, may contribute to tumor progression. This 
study shows that: i) some established pancreatic carcinoma 
cell lines, e.g. BxPC-3, express both TSLP mRNA and 
protein; ii) TSLP-rich CM from BxPC-3 cells, in a portion 
of normal DCs generated ex vivo, induce expression of the 
Th2 polarizing molecule OX40L, partially reversed in the 
presence of a neutralizing anti-TSLP polyclonal antibody; 
iii) both tumor infiltrating inflammatory cells and PDAC 
cells express the OX40L molecule; iv) abnormally 
elevated TSLP levels may exist in situ in tumor cells 
and, systemically, in locally-advanced/metastatic PDAC 
patients; v) among patients on different chemotherapeutic 
protocols, those receiving GEMOX display significantly 
elevated circulating TSLP levels; vi) circulating TSLP 
levels show promise as a diagnostic predictor for PDAC; 
vii) increased plasma TSLP is an independent prognostic 
risk factor for poor outcome.
It is increasingly clear that TSLP, known to be 
important in allergy, is also critically involved in the control 
of tumor growth and metastasis, having different effects 
depending on context, cellular source, and target [17]. In 
addition, it has been recently proposed that two isoforms 
of TSLP, exhibiting distinct or even opposite functions, 
exist in humans. The constitutive short isoform appears to 
mediate homeostatic functions, while the inducible long 
isoform is upregulated during inflammation [20].
The study shows that, of three PDAC cell lines 
analyzed (Capan-2, PT-45 and BxPC-3), only the latter 
synthesized relevant levels of TSLP. Interestingly, both 
in vitro study and flow cytometry analysis found that 
some normal myeloid DCs, generated ex vivo in the 
presence of BxPC-3 cell-CM (but not in that of TSLP-
negative Capan-2 cell-CM) express OX40L, a molecule 
fundamental for optimal induction of primary and memory 
Th2 responses. However, this effect was only attenuated 
when the BxPC-3 cell-CM was pre-treated with a 
neutralizing anti-TSLP polyclonal antibody. This antibody 
recognizes both short and long TSLP isoforms, suggesting 
that, in PDAC, TSLP is not the only factor conditioning 
DCs for Th2 priming. This hypothesis appears reasonable, 
taking into account that the cytokine IL-18 - one of the 
most important Th1 cytokines in the presence of IL-12, but 
that, in its absence, behaves as the Th2 cytokine - induces 
OX40L in DCs [21]. PDAC cells, both in vitro and in situ, 
constitutively express IL-18 [5] which, therefore, in this 
context may induce DCs to drive Th2 cells, cooperatively 
with TSLP. 
The human tissue microarray study shows that most 
of the PDAC tissues analyzed expressed TSLP protein at 
both malignant-cell and stroma levels.. The present study 
demonstrated that, in addition to CAFs [16], PDAC cells 
directly produce TSLP in vivo, suggesting further immune-
response manipulation in promoting tumor growth in the 
tumor itself. 
TSLP elaboration is not solely a PDAC-cell-
associated phenomenon. An increasing number of studies 
have focused on the complicated role of TSLP in several 
cancers: it is tumor-promoting in some instances, and 
Table 1: Plasma levels of TSLP pre- and post-treatment
Therapeutic protocol TSLP, pg/ml p e
Time 0a  Time 1b
Total patients treated (n = 62)c 4.95 (0–107.9)d 4.74 (0–182.06) 0.364
GEM 4.97 (0–14.82) 3.11 (0–16.28) 0.505
GEMOX 4.88 (0–107.91) 4.90 (0–182.06) 0.044
aPre-chemotherapy;
bPost-chemotherapy (first restaging).
cGEM (n = 27), GEMOX (n = 32), bolus 5-FU + Levofolinate Calcium (n = 2), and BEV+CAPE+RT (n = 1).
dMedian (range) plasma levels measured by ELISA. 
eWilcoxon matched pairs test.
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tumor-inhibiting in others. It has been shown that breast-
cancer-derived TSLP, but not tumor-infiltrating fibroblasts, 
drives tumor-promoting inflammatory Th2 cells present 
in the malignant microenvironment [22]. In lung cancer 
tissue, increased levels of TSLP appear to be involved in 
the marked prevalence of immunosuppressive CD4+CD25+ 
Treg cells, which might help tumor cells escape the host 
immune system [23]. Notably, this finding might explain 
the concomitant presence of circulating DCs polarized into 
a tolerogenic phenotype, and the expanded Treg pool found 
in PDCA patients [4, 6]. Moreover, TSLP produced by 
cervical cancer cells may promote angiogenesis [24, 25], 
and down-regulate miR-132 expression, favoring tumor 
development [26]. The involvement of TSLP in tumor 
growth is also supported by several murine experimental 
studies, in which tumor growth was inhibited in TSLP-
deficient hosts [27, 28]. Conversely, recent investigations 
in mouse models, and in early-breast and pancreatic 
human tumors [29], skin cancer [30, 31] and colon cancer 
[32], suggest a tumor-suppressing effect for TSLP.
The existence of two isoforms of TSLP controlled 
by two different promoter regions, and responsible for two 
opposing biological actions, may explain this paradoxical 
role of TSLP in malignancies. In the light of this recent 
finding, since the IHC analysis on PDAC tissue samples 
reported here did not distinguish between the two TSLP 
isoforms, and no correlation was found between TLPS 
protein expression levels and disease stage, the potential 
roles of the two isoforms in this disease remains to be 
determined. However, it appears likely that local quantitative 
and/or qualitative perturbations in the TSLP isoform or TSLP 
receptor expression may be an initiating and/or driving force, 
contributing to cancer formation and progression. 
To complement the present in vitro studies on the 
contribution of TSLP-rich CM from malignant pancreatic 
cells to OX40L+ DC generation, IHC analysis on PDAC 
tissue microarray was performed to determine the presence 
of the OX40L molecule in cell infiltrate of primary PDAC. 
Most tumors were infiltrated with OX40L+ cells, likely 
DCs; these, among tumor-infiltrating cells with APC 
capability, have both the numerical advantage and the 
broadest range of antigen presentation [33]. Surprisingly, 
OX40L expression was not restricted to immune-system 
related cells, but in several cases was also similarly present 
in both normal and tumor cells.
The role of OX40L in the polarization of Th cells is 
complex. OX40L is not constitutively expressed, but can 
be induced on APCs upon CD40 and Toll-like receptor 
engagement or cytokine signals. TSLP and IL-18 have 
been shown to potently induce OX40L expression on 
DCs [14, 34]. The molecule appears to play a universal 
and essential function in generating Th2 responses [14], 
whereas it may be connected to a Th1 response, though 
not always playing a paramount role [35].
Figure 6: Kaplan–Meier curves estimate overall survival for PDAC patients with <9.29 pg/ml (n = 59) and >9.29 pg/
ml (n = 23) TSLP levels. The significant difference between the two groups is shown (Log Rank Test).
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OX40L-expressing cells infiltrating the PDAC site 
may contribute to create inadequate or immunosuppressive 
events, with the help of OX40+ Treg cells accumulating 
in the tumor tissue; they may also enhance chronic 
inflammatory responses, promoting tumor invasion 
and metastasis. Conversely, OX40L+ cancer cells can 
exploit pathways present in normal tissue to establish a 
microenvironment facilitating tumor development. 
Unexpectedly, OX40L expression levels in the 
PDAC tissue samples were not correlated with those of 
TSLP, evaluated in parallel. However, this is in line with in 
vitro results, where OX40L-induction on DCs, generated 
in the presence of BxPC-3 cell-CM, was only partially 
TSLP-dependent. It provides further evidence that, in 
PDAC as in allergic inflammation, local TSLP-activated 
DCs can promote Th2 differentiation in a unique manner 
(dependent on OX40L and on the lack of production of 
IL-12), and that IL-18 may cooperatively potentiate 
the inflammatory Th2 cell responses, furthering tumor 
progression. 
Since TSLP is a secreted protein, and is highly 
expressed in pancreatic tumor tissues, plasma TSLP levels 
were measured in a group of locally-advanced/metastatic 
PDAC patients, and its potential clinical significance was 
assessed. It emerged, for the first time, that circulating 
TSLP (irrespectively of its biological activity) was 
significantly elevated in PDAC patients in comparison 
with normal subjects, independently of disease stage. The 
patients enrolled in this systemic analysis had advanced 
disease. In the light of the results of the in situ study 
performed by IHC on early stage PDAC tissue samples 
(in prevalence I/II stages), it is tempting to speculate that 
TSLP release occurs early in PDAC tumorigenesis and, 
once established, remains constant during the late phase 
of tumor progression. 
This is contrasted by findings reported by Demehri 
et al. in a murine model: TSLP-stimulated CD4+ Th2 
cells were found to be key mediators of the antitumor 
immune response that blocks early stages of both breast 
and pancreatic cancer development, protecting the animals 
from advanced cancer and metastasis. In particular, in 
the presence of systemic TSLP, spontaneous pancreatic 
tumors transferred to K14-TSLPtg mice grew less than 
those in WT mice, with a significant increase in GATA3+ 
Th2 infiltrating cell numbers [29]. 
However, these two possibilities are not 
contradictory, taking into account emerging evidence that 
TSLP exists in two different isoforms exerting opposing 
biological effects. It is thus tempting to hypothesize that, 
in early-stage PDAC, the prevalence of the short TSLP 
isoform, predominantly produced by cells that are still 
well/moderately-differentiated, may control tumor growth. 
But, in response to as-yet-unidentified stimuli altering the 
local microenvironment, the induced long TSLP isoform 
then takes over, affecting the course of the disease. At 
the systemic level, altered circulating levels of TSLP 
may negatively influence the frequency, composition, 
and functional activity of DC populations in vivo. This 
assumption is corroborated by ex vivo experiments 
showing that DCs from healthy subjects, generated in the 
presence of BxPC-3 cell-CM containing TSLP, expressed 
higher levels of OX40L surface. The mechanisms 
regulating TSLP expression and secretion from cancer 
cells, including a potential link with oncogenic events, 
remain to be established. 
Interestingly, univariate and multivariate 
analysis showed elevated circulating TSLP levels to be 
significantly associated with poorer survival, and to be 
an independent indicator of prognosis, respectively. As 
yet, no directly comparable data are available. However, 
in WT mice, serum levels of TSLP correlated positively 
with malignant breast-tumor cells and melanoma growth, 
indicating the importance of TSLP in tumor progression 
[27]. Moreover, in gastric cancer, TSLP is closely related 
to tumor progression and poor survival [36]. 
In investigating the ability of TSLP to discriminate 
between patients and controls, ROC analysis showed that 
the cutoff value of 4.76 ng/ml had the greatest diagnostic 
accuracy. However, further longitudinal data are required 
to confirm this observation. 
Systemic chemotherapy still remains a standard of 
care for the treatment of PDAC patients with unresectable 
locally-advanced and metastatic disease. In this study, 
among the several therapeutic protocols used, only the 
double-drug combination GEMOX was found to modulate 
plasma TSLP levels. These results are in line with 
research showing that chemotherapeutic agents may have 
immunomodulating properties and functional interactions 
[37]. However, unlike GEM monotherapy, which is 
generally used as adjuvant treatment after radical surgery, 
the GEMOX regimen is administered in unresectable 
advanced/metastatic disease. Thus the increase in plasma 
TSLP levels could be linked to chemo-resistance due to 
the more aggressive tumor cell behavior, given that the 
unresponsive patients under GEMOX treatment showed 
slightly increased circulating levels of TSLP. 
Although this patient series is not extensive, when 
the clinical response to different treatments is evaluated 
some tentative findings emerge. The clinical response to 
GEMOX (which is associated to a rise in plasma TSLP 
levels) was less favorable than GEM alone. However, 
pretreatment circulating TSLP levels did not predict the 
response to any regimen. 
Taken together, these clinical observations are 
consistent with the hypothesis that, in advanced-stage 
PDAC, high local and peripheral TSLP levels could have 
undesirable effects, producing an immune response that 
is both inappropriate and persistent. This assumption is 
highlighted by the importance of TSLP as an independent 
prognostic factor. Further investigation will thus be needed, 
in a large cohort of patients with early-stage operable cancer. 
The goals of cancer immunotherapy are to 
activate and expand tumor-specific CD4+ and CD8+ T 
cells, as an effective means of augmenting immunity 
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and overcoming mechanisms used by tumors to evade 
destruction. The results of this study are consistent 
with the notion that local and systemic tumor-derived 
TSLP may, with other concomitant immune-suppressive 
cytokine pathways, contribute to limiting the anti-tumor 
therapeutic responses to DC-based vaccines in PDAC. 
However, TSLP’s emerging ambiguous role in tumor 
immunology complicates the decision over how to 
manipulate TSLP, or its signaling pathway, in managing 
cancer patients. Additional studies will be required to 
reveal the mechanistic basis of the tumor-promoting vs. 
tumor-suppressive effects of TSLP in different cancers, 
before TSLP can be recognized as a potential target for 
therapeutic intervention. 
MATERIALS AND METHODS 
Normal and PDAC-established cell lines and 
preparation of conditioned media (CM) 
PDAC-derived cell lines Capan-2, BxPC-3 (ATCC 
HTB-80 and CRL-1687) and PT-45 (kindly provided by 
Prof. M. F. Di Renzo, Institute for Cancer Research and 
Treatment, Candiolo, Italy) were cultured in RPMI 1640 
medium supplemented with 10% FCS (Thermo Fisher 
Scientific, MA, USA) and regularly tested for mycoplasma 
contamination using Hoechst dye H33258 (Sigma Aldrich, 
MO, USA). Immortalized human pancreatic ductal epithelial 
cells HPDE6-E6E7 (H6c7) were generously provided by 
Dr. Ming-Sound Tsao, Cancer Center/Princess Margaret 
Hospital, University Health Network, Toronto, Ontario, 
Canada [38]. CM were obtained as described elsewhere [39].
Patients
The series comprised 82 patients with locally-
advanced or metastatic PDAC admitted to the Department 
of Medical Oncology, Città della Salute e della Scienza 
Hospital, Turin, Italy, enrolled into the study between May 
2010 and March 2012; patients with serious infections 
or severe allergic disease were excluded. None of the 
participants had received chemo/radio therapy before 
entering the study. All participants signed an informed 
consent form; study procedures were in accordance with 
the Declaration of Helsinki. Before starting chemotherapy, 
patients were staged following the International Union 
Against Cancer (UICC) TNM system. Patients’ clinical-
pathological details are in Table 2. Of the 82 patients, 
23 underwent radical surgery followed by adjuvant 
chemotherapy; 5 received palliative surgical treatment 
followed immediately by chemotherapy; 54 patients, 
judged unsuitable for surgery, received palliative 
chemotherapy. Six patients received no antitumor 
treatment because of the rapid clinical progression of 
their disease. Patients were subjected to the following 
chemotherapeutic protocols: gemcitabine (GEM) (1250 
mg/m2 on days 1 and 8 every 21 days); GEM (1000 mg/
m2 on day 1) plus oxaliplatin (OX) (100 mg/m2 on day 
2 every 14 days); bevacizumab (5 mg/kg every 14 days) 
plus capecitabine (825 mg/m2/b.i.d.) and concomitant 
radiotherapy (50.4 Gy in 28 cycles) (BEV+CAPE+RT), 
following the study protocol; 5-fluorouracil (5-FU) 
(500 mg/m2) plus levofolinate calcium (250 mg/m2 on 
days 1, 8, and 15 every 28 days). After the first restaging, 
responses (assessed by the RECIST criteria) were as 
follows: 2 complete remission (CR), 4 partial remission 
(PR), 32 stable disease (SD) and 31 disease progression 
(PD) (in 7 cases clinical progression was not documented 
radiologically). 
Patient follow-up continued until death or March 
2012. 65 patients died (median survival 242.5 days; range 
43–836). 17 patients were alive at completion of the study. 
Survival was 51.2% at 1 year after diagnosis. 
Cell isolation and generation of DCs
Peripheral blood mononuclear cells (PBMC) were 
isolated from heparinized blood samples from healthy 
donors (n = 10). Ex vivo-generated DCs were obtained as 
described elsewhere [4], in the presence or absence of 20% 
Capan-2 and BxPC-3 cell-CMs. In selected experiments, 
DCs were generated in the presence of 20% BxPC-3 cell-
CM, pre-treated or not with neutralizing polyclonal antibody 
against TSLP (R&D Systems, Minneapolis, MN, 40 ng/ml 
final dilution), or with an appropriate irrelevant antibody. 
Depletion of TSLP using Protein A/G-coated 
agarose beads
Neutralizing polyclonal antibody against TSLP 
(R&D Systems) or irrelevant control IgG were added to 
BxPC-3 cell-CM at the concentration used to neutralize 
TSLP biological activity (40 ng/ml) as reported 
above. Samples were incubated for 30 min at r.t. After 
addition of Protein A/G agarose beads (Thermo Fisher 
Scientific) (50 µl/ml per CM, amount exceeding the 
binding capacity of 250 µg of antibody) the samples 
were incubated o.n. at 4° C under agitation, and then 
centrifuged twice at 420 g for 5 min to ensure complete 
removal of agarose beads. 
Determination of TSLP levels
TSLP was measured in the CM of PDAC cell lines 
and in plasma from PDAC patients and healthy donors, 
as well as in Bx-PC-3 cell-CM depleted of TSLP by 
immunoprecipitation, using an ELISA kit (Thermo Fisher 
Scientific). Minimum detectable quantity: 8 pg/ml. The 
manufacturer of the ELISA kit was not able to indicate the 
TSLP isoform recognized.
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RNA isolation and real time reverse-transcription 
polymerase chain reaction (RT–PCR)
Total RNA was extracted from Capan-2, BxPC-
3 and PT-45 cell lines, and from appropriate positive 
controls, using TRIzol Reagent (Thermo Fisher Scientific). 
To remove traces of genomic DNA, total RNAs (1 µg) 
were treated with DNase I and reverse-transcribed to 
cDNAs using SuperScript II (Thermo Fisher Scientific). 
Real time RT-PCR was performed in duplicate 
using SYBR Green real time PCR master mix (Bio-Rad, 
CA, USA) in iCycler iQ system (Bio-Rad). The specific 
primers used to amplify TLPS and β-actin genes were, 
respectively: FW: CGTGGTGGGAAGAGTTTA and RW: 
CAGTTAGTGAAGTCGTAAGT; FW: GCGAGA 
AGATGACCCAGATC and RW: GGATAGCAC 
AGCCTGGATAG. TSLP RNA expression levels, reported 
as arbitrary units relative to β-actin, were calculated by 
Table 2: Patients’ clinical and pathological features






Age (y)  66.2 ± 9.2
Disease stage at start of chemotherapy









































Type of chemotherapy 
GEM
GEMOX



















Age data are presented as the mean ± standard deviation and other data as the number (percentage).
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the Gene Expression Analysis Real-Time PCR Detection 
System Ò Software Tool for iCycler iQ (Bio-Rad).
Flow cytometric analysis
Expression of OX40L (CD252) was analyzed on 
normal DCs generated in the conditions reported above. 
The cells were double stained with a phycoerythrin-
cyanine 5.1 (PC5)-conjugated anti-HLA-DR monoclonal 
antibody (mAb) (clone ID: Immu-357, Beckman Coulter, 
CA, USA) and fluorescein isothiocyanate (FITC) anti-
OX40L mAb (clone ID: 159403, R&D Systems). Cells 
were analyzed by flow cytometry in a Coulter Epics 
XL Cytometer (Beckman Coulter) using the Expo32 
software (Beckman Coulter). Results are expressed as the 
percentage of OX40L+ cells in the fraction of HLA-DR+ 
cells. Statistical analyses were based on at least 30,000 
events gated on the population of interest.
Immunohistochemistry (IHC)
Commercial tissue microarrays (TMA) containing 
38 PDAC tissue samples (n = 11 well-differentiated, 
n = 2 moderately-differentiated, n = 1 moderately/poorly-
differentiated, n = 3 poorly-differentiated; from 13 male 
and 25 female patients, aged 41–74 years, median age 
67.5; n = 9 disease stage I, n = 23 stage II, n = 2 stage 
III, and n = 3 stage IV) and 8 healthy pancreatic tissue 
samples (2 male and 6 female donors, aged 31–41 years, 
median age 35) (U.S. Biomax, MD, USA) were used 
to identify and localize TSLP and OX40L proteins by 
IHC. TMA slides were processed for IHC as described 
elsewhere [5]. Following incubation with a rabbit mAb 
against human TSLP (clone ID: EPR4191, Epitomics, CA, 
USA) and a mouse mAb against human OX40L (clone 
ID: 15940, R&D Systems), the sections were stained 
using peroxidase-based visualization DAKO LSAB® kit 
(Dako, Denmark). Staining intensity was evaluated by 
a semiquantitative method, using the immunoreacting 
score (IRS) proposed by Remmele and Stegner [40], in 
which IRS = SI (staining intensity) x PP (percentage of 
positive cells). SI was assigned as: 0 = negative; 1 = weak; 
2 = moderate; 3 = strong. PP was assigned as: 0 = 
negative; 1 = 1–20% positive cells; 2 = 21–50% positive 
cells; 3 = 51–100% positive cells. Ten visual fields from 
different areas of each specimen were chosen at random 
for IRS evaluation.
Statistical analysis
The Mann-Whitney Rank Sum Test, Kruskal-Wallis 
One Way Analysis of Variance by Ranks or Student’s t-test 
were used to evaluate statistically-significant differences 
between datasets. Correlations were analyzed by the 
Spearman Test. Overall patient survival was defined as the 
time from the date of diagnosis to the date of last follow-
up (censored) or patient death from any cause. Survival 
probabilities were calculated using the Kaplan–Meier 
Method. Survival curves were compared using the Log-
Rank Test (Mantel-Cox). The feasibility of using plasma 
TSLP as a biomarker for differentiating cases from normal 
controls was assessed by receiver-operating characteristic 
(ROC) curve analysis. P values < 0.05 were considered 
statistically significant. Statistical analysis was performed 
with SPSS Statistics for Windows, Version 22.0 (SPSS Inc, 
IL, USA).
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